A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI
regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.
Phase:
N/A
Details
Lead Sponsor:
University of South Florida
Collaborators:
Merck Sharp & Dohme Corp. St. Joseph's Hospital, Florida